These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 17486245)
41. Nanocarriers for effective delivery of benznidazole and nifurtimox in the treatment of chagas disease: A review. Arrúa EC; Seremeta KP; Bedogni GR; Okulik NB; Salomon CJ Acta Trop; 2019 Oct; 198():105080. PubMed ID: 31299283 [TBL] [Abstract][Full Text] [Related]
42. Serological response to nifurtimox in adult patients with chronic Chagas disease: An observational comparative study in Argentina. Vizcaya D; Grossmann U; Kleinjung F; Zhang R; Suzart-Woischnik K; Seu S; Ramirez T; Colmegna L; Ledesma O PLoS Negl Trop Dis; 2021 Oct; 15(10):e0009801. PubMed ID: 34606501 [TBL] [Abstract][Full Text] [Related]
43. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. Molina I; Gómez i Prat J; Salvador F; Treviño B; Sulleiro E; Serre N; Pou D; Roure S; Cabezos J; Valerio L; Blanco-Grau A; Sánchez-Montalvá A; Vidal X; Pahissa A N Engl J Med; 2014 May; 370(20):1899-908. PubMed ID: 24827034 [TBL] [Abstract][Full Text] [Related]
44. Nifurtimox (Lampit) for Chagas disease. Med Lett Drugs Ther; 2024 Jul; 66(1707):e123-e124. PubMed ID: 39137168 [No Abstract] [Full Text] [Related]
45. Evaluation of Parasiticide Treatment with Benznidazol in the Electrocardiographic, Clinical, and Serological Evolution of Chagas Disease. Fragata-Filho AA; França FF; Fragata Cda S; Lourenço AM; Faccini CC; Costa CA PLoS Negl Trop Dis; 2016 Mar; 10(3):e0004508. PubMed ID: 26974551 [TBL] [Abstract][Full Text] [Related]
46. Specific chemotherapy of Chagas disease: a comparison between the response in patients and experimental animals inoculated with the same strains. Andrade SG; Rassi A; Magalhaes JB; Ferriolli Filho F; Luquetti AO Trans R Soc Trop Med Hyg; 1992; 86(6):624-6. PubMed ID: 1287919 [TBL] [Abstract][Full Text] [Related]
48. Chagas cardiomyopathy associated with serological cure after trypanocidal treatment during childhood. Fernández ML; Hernández Y; Scollo K; Esteva MI; Riarte AR; Prado NG Rev Soc Bras Med Trop; 2018; 51(4):557-559. PubMed ID: 30133646 [TBL] [Abstract][Full Text] [Related]
49. Pediatric clinical pharmacology studies in Chagas disease: focus on Argentina. Garcia-Bournissen F; Altcheh J; Giglio N; Mastrantonio G; Della Védova CO; Koren G Paediatr Drugs; 2009; 11(1):33-7. PubMed ID: 19127950 [TBL] [Abstract][Full Text] [Related]
50. The effect of benznidazole dose among the efficacy outcome in the murine animal model. A quantitative integration of the literature. Molina I; Perin L; Aviles AS; de Abreu Vieira PM; da Silva Fonseca K; Cunha LM; Carneiro CM Acta Trop; 2020 Jan; 201():105218. PubMed ID: 31610148 [TBL] [Abstract][Full Text] [Related]
51. Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO). Altcheh J; Castro L; Dib JC; Grossmann U; Huang E; Moscatelli G; Pinto Rocha JJ; Ramírez TE; PLoS Negl Trop Dis; 2021 Jan; 15(1):e0008912. PubMed ID: 33412557 [TBL] [Abstract][Full Text] [Related]
52. Reversibility of muscle and heart lesions in chronic, Trypanosoma cruzi infected mice after late trypanomicidal treatment. Segura MA; Molina de Raspi E; Basombrio MA Mem Inst Oswaldo Cruz; 1994; 89(2):213-6. PubMed ID: 7885247 [TBL] [Abstract][Full Text] [Related]
53. Persistent infections in chronic Chagas' disease patients treated with anti-Trypanosoma cruzi nitroderivatives. Braga MS; Lauria-Pires L; Argañaraz ER; Nascimento RJ; Teixeira AR Rev Inst Med Trop Sao Paulo; 2000; 42(3):157-61. PubMed ID: 10887376 [TBL] [Abstract][Full Text] [Related]
54. [Evaluation of complement mediated lysis technic in patients with chronic Chagas' disease treated with trypanocidal drugs]. Levy AM; Pereira VL; Boainain E Rev Inst Med Trop Sao Paulo; 1988; 30(1):32-9. PubMed ID: 3146793 [No Abstract] [Full Text] [Related]
55. An update on benznidazole for the treatment of patients with Chagas disease. Thakare R; Dasgupta A; Chopra S Drugs Today (Barc); 2018 Jan; 54(1):15-23. PubMed ID: 29569658 [TBL] [Abstract][Full Text] [Related]
56. Lack of sensitivity of sister-chromatid exchange for lymphocyte chromosomal damage detection caused by antichagasic treatment. Gorla NB; Ledesma OS; Barbieri GP; Larripa IB Toxicol Lett; 1991 Oct; 58(2):225-30. PubMed ID: 1949081 [TBL] [Abstract][Full Text] [Related]
57. Evaluation of nifurtimox treatment of chronic Chagas disease by means of several parasitological methods. Muñoz C; Zulantay I; Apt W; Ortiz S; Schijman AG; Bisio M; Ferrada V; Herrera C; Martínez G; Solari A Antimicrob Agents Chemother; 2013 Sep; 57(9):4518-23. PubMed ID: 23836179 [TBL] [Abstract][Full Text] [Related]
58. Characteristics of Patients for Whom Benznidazole Was Released Through the CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease - United States, 2011-2018. Herwaldt BL; Dougherty CP; Allen CK; Jolly JP; Brown MN; Yu P; Yu Y MMWR Morb Mortal Wkly Rep; 2018 Jul; 67(29):803-805. PubMed ID: 30048425 [TBL] [Abstract][Full Text] [Related]
59. Lytic antibody titre as a means of assessing cure after treatment of Chagas disease: a 10 years follow-up study. Galvao LM; Nunes RM; Cançado JR; Brener Z; Krettli AU Trans R Soc Trop Med Hyg; 1993; 87(2):220-3. PubMed ID: 8337734 [TBL] [Abstract][Full Text] [Related]
60. Current drug therapy and pharmaceutical challenges for Chagas disease. Bermudez J; Davies C; Simonazzi A; Real JP; Palma S Acta Trop; 2016 Apr; 156():1-16. PubMed ID: 26747009 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]